Clinical Trials /

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

NCT02143414

Description:

This phase II trial studies the side effects and how well blinatumomab and combination chemotherapy or dasatinib, prednisone, and blinatumomab work in treating older patients with acute lymphoblastic leukemia. Immunotherapy with blinatumomab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as prednisone, vincristine sulfate, methotrexate, and mercaptopurine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving blinatumomab with combination chemotherapy or dasatinib and prednisone may kill more cancer cells.

Related Conditions:
  • B-Cell Acute Lymphoblastic Leukemia
Recruiting Status:

Recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
  • Official Title: A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)

Clinical Trial IDs

  • ORG STUDY ID: NCI-2014-01047
  • SECONDARY ID: NCI-2014-01047
  • SECONDARY ID: SWOG-S1318
  • SECONDARY ID: S1318
  • SECONDARY ID: S1318
  • SECONDARY ID: U10CA180888
  • NCT ID: NCT02143414

Conditions

  • Acute Lymphoblastic Leukemia
  • B Acute Lymphoblastic Leukemia
  • B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
  • Recurrent Adult Acute Lymphoblastic Leukemia
  • Refractory Adult Acute Lymphoblastic Leukemia

Interventions

DrugSynonymsArms
BlinatumomabAnti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI-538, MT-103Cohort I (blinatumomab, POMP)
DasatinibBMS-354825, SprycelCohort II (dasatinib, prednisone, blinatumomab)
Mercaptopurine3H-Purine-6-thiol, 6 MP, 6 Thiohypoxanthine, 6 Thiopurine, 6-Mercaptopurine, 6-Mercaptopurine Monohydrate, 6-MP, 6-Purinethiol, 6-Thiopurine, 6-Thioxopurine, 6H-Purine-6-thione, 1,7-dihydro- (9CI), 7-Mercapto-1,3,4,6-tetrazaindene, Alti-Mercaptopurine, Azathiopurine, BW 57-323H, Flocofil, Ismipur, Leukerin, Leupurin, Mercaleukim, Mercaleukin, Mercaptina, Mercaptopurinum, Mercapurin, Mern, NCI-C04886, Puri-Nethol, Purimethol, Purine, 6-mercapto-, Purine-6-thiol (8CI), Purine-6-thiol, monohydrate, Purinethiol, Purinethol, U-4748, WR-2785Cohort I (blinatumomab, POMP)
MethotrexateAbitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039Cohort I (blinatumomab, POMP)
Prednisone.delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-PrednisoneCohort I (blinatumomab, POMP)
VincristineLEUROCRISTINE, VCR, VincrystineCohort I (blinatumomab, POMP)
Vincristine SulfateKyocristine, Leurocristine sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfateCohort I (blinatumomab, POMP)

Purpose

This phase II trial studies the side effects and how well blinatumomab and combination chemotherapy or dasatinib, prednisone, and blinatumomab work in treating older patients with acute lymphoblastic leukemia. Immunotherapy with blinatumomab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as prednisone, vincristine sulfate, methotrexate, and mercaptopurine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving blinatumomab with combination chemotherapy or dasatinib and prednisone may kill more cancer cells.

Detailed Description

      PRIMARY OBJECTIVES:

      I. To evaluate the 3-year survival rate in elderly patients with newly diagnosed Philadelphia
      (Ph)-negative acute lymphoblastic leukemia (ALL) treated with blinatumomab followed by POMP
      (prednisone, vincristine sulfate, methotrexate, and mercaptopurine) maintenance.

      II. To evaluate in a preliminary manner (feasibility study) the safety of dasatinib-steroid
      based induction followed by blinatumomab treatment in combination with dasatinib followed by
      dasatinib-based maintenance in patients with newly diagnosed Ph-positive ALL,
      relapsed/refractory Ph-positive ALL, and Ph-like dasatinib-sensitive mutations or kinase
      fusions (DSMKF) ALL (newly-diagnosed relapsed or refractory).

      SECONDARY OBJECTIVES:

      I. To evaluate toxicities in these patient populations treated with these regimens.

      II. To estimate the rates of complete response (CR), complete remission with incomplete count
      recovery (CRi) and disease-free survival in Ph-negative patients.

      III. To estimate disease-free and overall survival in Ph-positive ALL and Ph-like DSMKF ALL.

      IV. To estimate in each cohort the rate of minimal residual disease (MRD) negativity, and the
      time to achieve MRD negativity (exploratory analysis).

      V. To determine whether anti-idiotype antibodies directed against blinatumomab develop with
      blinatumomab treatment in this study.

      OUTLINE: Patients are assigned to 1 of 2 treatment cohorts according to Philadelphia
      chromosome status.

      COHORT I (PHILADELPHIA CHROMOSOME NEGATIVE PATIENTS):

      INDUCTION: Patients receive blinatumomab intravenously (IV) continuously over 24 hours on
      days 1-28 in the absence of disease progression or unacceptable toxicity.

      RE-INDUCTION: Patients not achieving CR or CRi after Induction, receive blinatumomab IV
      continuously over 24 hours on days 1-28 in the absence of disease progression or unacceptable
      toxicity.

      POST-REMISSION: Patients receive blinatumomab IV continuously over 24 hours on days 1-28.
      Treatment repeats every 42 days for 3 cycles in the absence of disease progression or
      unacceptable toxicity.

      MAINTENANCE: Patients receive prednisone orally (PO) on days 1-5, vincristine sulfate IV on
      day 1, mercaptopurine PO on days 1-28, and methotrexate PO on days 1, 8, 15, and 22.
      Treatment repeats every 28 days for 18 cycles in the absence of disease progression or
      unacceptable toxicity.

      COHORT II (PHILADELPHIA CHROMOSOME POSITIVE PATIENTS):

      INDUCTION: Patients receive dasatinib PO twice daily (BID) on days 1-84 and prednisone PO on
      days 1-24 with tapering on days 25-32 in the absence of disease progression or unacceptable
      toxicity.

      RE-INDUCTION: Patients receive blinatumomab IV continuously over 24 hours on days 1-28.
      Treatment repeats every 42 days for 2 cycles in the absence of disease progression or
      unacceptable toxicity.

      POST-REMISSION: Patients receive blinatumomab IV continuously over 24 hours on days 1-28 and
      dasatinib PO once daily (QD) on days 1-42. Treatment repeats every 42 days for 3 cycles in
      the absence of disease progression or unacceptable toxicity.

      MAINTENANCE: Patients receive dasatinib PO BID on days 1-28 and prednisone PO on days 1-5.
      Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months for 2 years,
      every 6 months for 2 years, and then annually until 10 years from initial registration.
    

Trial Arms

NameTypeDescriptionInterventions
Cohort I (blinatumomab, POMP)ExperimentalINDUCTION: Patients receive blinatumomab IV continuously over 24 hours on days 1-28 in the absence of disease progression or unacceptable toxicity. RE-INDUCTION: Patients not achieving CR or CRi after Induction, receive blinatumomab IV continuously over 24 hours on days 1-28 in the absence of disease progression or unacceptable toxicity. POST-REMISSION: Patients receive blinatumomab IV continuously over 24 hours on days 1-28. Treatment repeats every 42 days for 3 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive prednisone PO on days 1-5, vincristine sulfate IV on day 1, mercaptopurine PO on days 1-28, and methotrexate PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 18 cycles in the absence of disease progression or unacceptable toxicity.
  • Blinatumomab
  • Mercaptopurine
  • Methotrexate
  • Prednisone
  • Vincristine
  • Vincristine Sulfate
Cohort II (dasatinib, prednisone, blinatumomab)ExperimentalINDUCTION: Patients receive dasatinib PO BID on days 1-84 and prednisone PO on days 1-24 with tapering on days 25-32 in the absence of disease progression or unacceptable toxicity. RE-INDUCTION: Patients receive blinatumomab IV continuously over 24 hours on days 1-28. Treatment repeats every 42 days for 2 cycles in the absence of disease progression or unacceptable toxicity. POST-REMISSION: Patients receive blinatumomab IV continuously over 24 hours on days 1-28 and dasatinib PO QD on days 1-42. Treatment repeats every 42 days for 3 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive dasatinib PO BID on days 1-28 and prednisone PO on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
  • Blinatumomab
  • Dasatinib
  • Prednisone

Eligibility Criteria

        Inclusion Criteria:

          -  Registration Step 1 - Induction/Re-Induction:

          -  Patients must have a new morphologic diagnosis of precursor B cell acute lymphoblastic
             leukemia (ALL) (non T cell) based on World Health Organization (WHO) criteria;
             patients with Burkitt's (L3) are excluded; patients with Ph-positive or Ph-like ALL
             with dasatinib-sensitive mutations or kinase fusions may have relapsed or refractory
             diagnoses

               -  NOTE: Relapsed/refractory Ph-positive patients or Ph-like patients with
                  dasatinib-sensitive mutations or kinase fusions who have previous exposure to
                  either dasatinib or another 2nd or 3rd generation tyrosine kinase inhibitor (TKI)
                  will begin protocol therapy with Cohort 2: re-induction cycle 1

          -  Patients must have a diagnosis of Philadelphia chromosome negative ALL or Ph
             chromosome positive ALL by cytogenetics, fluorescence in situ hybridization (FISH) or
             polymerase chain reaction (PCR); patients will be registered to receive treatment in
             either Cohort 1 (ph-) or Cohort 2 (Ph+ or Ph-like DSMKF) based on these results;
             diagnostic specimens must be submitted to the site's local Clinical Laboratory
             Improvement Amendments (CLIA)-approved cytogenetics laboratory and results of tests
             (cytogenetics, FISH or PCR) must confirm Ph status prior to registration; if not
             already known, breakpoint cluster region- abelson murine leukemia viral oncogene
             homolog 1 (BCR-ABL) status (p190 or p210) must be evaluated in Ph-positive patients by
             PCR

               -  For Cohort 2, Ph-like testing is not required specifically for this study;
                  however, to be registered to Cohort 2 under the Ph-like DSMKF criterion, the
                  patient must have a known or presumed activating Ph-like signature and
                  dasatinib-sensitive mutation or kinase fusion, such as: ABL1, ABL2, colony
                  stimulating factor 1 receptor (CSF1R), platelet derived growth factor receptor
                  beta (PDGFRB), platelet derived growth factor receptor alpha (PDGFRA), or
                  fibroblast growth factor receptor (FGFR)s that was otherwise identified as part
                  of normal standard of care; prior to registering any patients with a known or
                  presumed activating Ph-like signature and dasatinib-sensitive mutations or kinase
                  fusions (DSMKF) treating physicians must confirm eligibility with the study
                  chairs via email; the study chairs must respond via email with confirmation of
                  patient eligibility prior to patient registration

          -  All newly diagnosed patients must have evidence of ALL in their marrow or peripheral
             blood with at least 20% lymphoblasts present in blood or bone marrow collected within
             28 days prior to registration; all relapsed/refractory patients (Cohort 2) must have
             at least 5% lymphoblasts present in blood or bone marrow collected within 28 days
             prior to registration; for relapsed/refractory patients, pathology and cytogenetics
             reports (both from time of original diagnosis) must be submitted at time of
             registration; if a bone marrow aspirate cannot be obtained despite an attempt (dry
             tap), appropriate immunohistochemistry (IHC) testing, including CD19, must be
             performed on the bone marrow biopsy to determine lineage; for ALL in marrow or
             peripheral blood, immunophenotyping of the blood or marrow lymphoblasts must be
             performed to determine lineage (B cell, T cell or mixed B/T cell); appropriate marker
             studies including cluster of differentiation (CD)19 (B cell), must be performed;
             co-expression of myeloid antigens (CD13 and CD33) will not exclude patients; if
             possible, the lineage specific markers (myeloid cells) should be determined; the
             blood/bone marrow sample for these assays must be obtained within 28 days prior to
             registration; patients with only extramedullary disease in the absence of bone marrow
             or blood involvement are not eligible

          -  Patient must not have a history or presence of clinically relevant central nervous
             system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe
             brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain
             syndrome, psychosis, active ALL in the CNS confirmed by cerebrospinal fluid (CSF)
             analysis, or other significant CNS abnormalities

          -  Patients must have a lumbar puncture to determine CNS involvement of ALL within 14
             days prior to registration; patients with CNS3 are excluded from the trial; patients
             with CNS1 or CNS2 will be eligible, but will be monitored for CNS involvement; note
             that intrathecal methotrexate administered during the pre-study lumbar puncture may
             count as the first dose of intrathecal therapy required as part of the study

          -  Cohort I, Ph-negative Patients Only: Patients must not have received any prior
             chemotherapy, radiation therapy, or other therapy for the treatment of ALL (other than
             those noted below) and must not be receiving any immunosuppressive therapy; patients
             may not have received any prior investigational therapy within 28 days prior to
             registration; patients must not have received any monoclonal antibody therapy within
             42 days of registration; patients may have received the following within any time
             prior to registration: low dose chemotherapy-including: cyclophosphamide 1 g/m^2, oral
             6-mercaptopurine, or oral methotrexate (other low dose chemotherapy may be allowable,
             however any other options not listed here should be confirmed with the study chairs),
             TKI therapy, steroids, hydroxyurea, leukapheresis, intrathecal chemotherapy or
             vincristine (vincristine sulfate)

          -  Cohort I, Ph-negative Patients Only: In the event that the patient's bone marrow blast
             count is >= 50% blasts, patients may be registered but should receive steroids for 3-5
             days in order to reduce tumor burden prior to blinatumomab administration, as follows

               -  Prephase treatment with dexamethasone (10-20 mg/m^2) for 3-5 days is required for
                  patients with bone marrow blasts >= 50%, peripheral blood blasts 15,000/uL or
                  higher, or elevated lactate dehydrogenase (LDH) suggesting rapidly progressive
                  disease per investigator opinion

                    -  Pre-treatment should conclude at least 24 hours prior to the first dose of
                       blinatumomab (although additional dexamethasone is automatically given as a
                       pre-med prior to the first dose); at the time of first infusion of
                       blinatumomab, the absolute peripheral blast count should be < 25,000/uL

                    -  Note: For the purposes of the study, day 1 of the cycle will be the first
                       day of blinatumomab administration

          -  Cohort I, Ph-negative Patients Only: It is preferred, but not required, that
             corticosteroids and hydroxyurea should start only after all diagnostic samples have
             been obtained; however, if the patient was previously on corticosteroids and/or
             hydroxyurea, this is allowable provided that the patient still has measurable disease
             at time of the bone marrow aspirate

               -  Corticosteroids and/or hydroxyurea, as well as any of the other therapies
                  mentioned (with the exception of IV cyclophosphamide), may continue to be
                  administered, at physician discretion, until 1 day prior to blinatumomab
                  administration

               -  IV cyclophosphamide must be discontinued at least 7 days prior to blinatumomab
                  administration

          -  Cohort 2, Ph-positive and Ph-like DSMKF Patients Only: Patients must NOT have received
             a prior autologous or allogeneic hematopoietic stem cell transplant at any time.
             Patients must NOT have received any chemotherapy, investigational agents, or undergone
             major surgery within 14 days prior to registration, with the following exceptions:

               -  Monoclonal antibodies must not have been received for 1 week prior to
                  registration

               -  Chimeric antigen receptor (CAR) T-cells must not have been received for 28 days
                  prior to registration

               -  Steroids, hydroxyurea, vincristine, 6-mercaptopurine, methotrexate, thioguanine
                  and intrathecal chemotherapy are permitted within any timeframe prior to
                  registration; Food and Drug Administration (FDA)-approved TKIs may also be
                  administered until 1 day prior to start of study therapy (C1, D1); IV
                  cyclophosphamide may be administered at doses of 1 g/m^2 or less until up to 7
                  days prior to registration

          -  For patients 65-69 years of age, patient must be deemed not suitable for standard
             intensive induction chemotherapy at the discretion of the local investigator, or must
             have refused standard intensive chemotherapy

          -  Cohort I, Ph-negative Patients Only: Patients must not be candidates for allogeneic
             hematopoietic stem cell transplant; NOTE: Subjects up to age 70 years who are
             considered fit for allogeneic hematopoietic stem cell transplant, should be considered
             for enrollment on E1910, in order to avoid competing with that study; if a patient is
             considered unfit for intensive chemotherapy at the time of initial diagnosis, but
             subsequently achieves a complete remission (CR), then it will be left to the treating
             physician's discretion to consider hematopoietic stem cell transplant (HSCT)

          -  Patients must have complete history and physical examination within 28 days prior to
             registration

          -  Patients must have a Zubrod performance status of 0-2

          -  Patients must have serum creatinine =< 1.5 mg/dl within 14 days prior to registration

          -  Patients must have aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
             =< 3.0 x institutional upper limit of normal (IULN) within 14 days prior to
             registration

          -  Patients must have total bilirubin =< 2.0 x IULN within 14 days prior to registration

          -  Patients must have alkaline phosphatase =< 2.5 x IULN within 14 days prior to
             registration

          -  Patients must not have systemic fungal, bacterial, viral or other infection that is
             not controlled (defined as exhibiting ongoing signs/symptoms related to the infection
             and without improvement, despite appropriate antibiotics or other treatment)

          -  Patients must not have Common Terminology Criteria for Adverse Events (CTCAE) >= grade
             2 neuropathy (cranial, motor or sensory) within 14 days prior to registration

          -  Patients known to be positive for HIV (the human immunodeficiency virus) may be
             eligible, providing they meet the following additional criteria within 28 days prior
             to registration:

               -  No history of acquired immune deficiency syndrome (AIDS)-defining conditions

               -  CD4 cells > 350 cells/mm^3

               -  If on antiretroviral agents, must not include zidovudine or stavudine

               -  Viral load =< 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on
                  combination antiretroviral therapy (cART) or =< 25,000 copies HIV mRNA/mm^3 if
                  not on cART

               -  Highly active antiretroviral therapy (HAART) regimens are acceptable providing
                  they have only weak P450A4 interactions

          -  Patients must not have any known autoimmune disease

          -  Patients must not have testicular involvement; if clinical or ultrasound findings are
             equivocal, biopsy must be performed; all tests for establishing testicular involvement
             must be completed within 14 days prior to registration

          -  Patients with evidence of extramedullary disease at diagnosis will have computed
             tomography (CT) scan or magnetic resonance imaging (MRI) of the chest, abdomen and
             pelvis to obtain baseline values within 28 days prior to registration

          -  No other prior malignancy is allowed except for the following: adequately treated
             basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
             stage I or II cancer from which the patient is currently in complete remission, or any
             other cancer from which the patient has been disease free for five years

          -  Patients must have the following tests within 28 days prior to registration to obtain
             baseline measurements:

               -  Prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized
                  ratio (INR)/fibrinogen (all patients)

               -  Cohort 1, Ph- Patients Only: Neurologic assessment

          -  Cohort 2, Ph+ and Ph-like DSMKF Patients Only: Patients must not have active
             pericardial effusion, ascites or pleural effusion of any grade based on chest x-ray
             and echocardiogram within 28 days prior to registration; exception: if the effusion is
             suspected to be related to the leukemia, the patient may have pericardial effusion =<
             grade 2 or pleural effusion =< grade 1

          -  Cohort 2, Ph+ and Ph-like DSMKF Patients Only: Patients must have ejection fraction >=
             45% based on echocardiogram performed within 28 days prior to registration

          -  Cohort 2, Ph+ and Ph-like DSMKF Patients Only: Patients must have QTcF (by Fridericia
             calculation) < 480/msec based on electrocardiogram (EKG) performed within 28 days
             prior to registration

          -  Cohort 2, Ph+ and Ph-like DSMKF Patients Only: Patients must not be receiving any
             proton pump inhibitors at the time of registration

          -  Pretreatment cytogenetics must be performed on all patients; collection of
             pretreatment specimens must be completed within 28 days prior to registration to
             S1318; specimens must be submitted to the site's preferred CLIA-approved cytogenetics
             laboratory; BCR-ABL status must be verified in Ph-positive patients by FISH,
             cytogenetics, and/or PCR prior to enrollment; if a patient is Ph-positive, PCR for
             both p190 and p210 must be sent

          -  Patients must be offered participation in specimen submission for future research;
             with patient's consent, specimens must be submitted as outlined

          -  Cohort 1, Ph-negative patients only: Patients must have specimens submitted for
             blinatumomab immunogenicity assessment; collection of pretreatment specimens must be
             completed within 28 days prior to registration to S1318; specimens must be submitted
             to LabConnect

          -  Cohort 2, Ph-positive and Ph-like DSMKF patients only: Patients must agree to have
             specimens submitted for blinatumomab immunogenicity testing if subsequently moved to a
             blinatumomab containing treatment regimen on protocol

          -  Patients or their legally authorized representative must be informed of the
             investigational nature of this study and must sign and give written informed consent
             in accordance with institutional and federal guidelines

          -  As a part of the Oncology Patient Enrollment Network (OPEN) registration process the
             treating institution's identity is provided in order to ensure that the current
             (within 365 days) date of institutional review board approval for this study has been
             entered in the system

          -  Registration Step 2 - Post-Remission Therapy:

          -  COHORT 1 PH-NEGATIVE PATIENTS ONLY: Patients must have achieved CR or CRi within 2
             cycles of induction/re-induction with blinatumomab

               -  NOTE: day 1 of post-remission = day 43 of the preceding cycle (+/- 3 days)

          -  COHORT 2 PH-POSITIVE AND PH-LIKE DSMKF PATIENTS ONLY: Newly diagnosed Ph+,
             newly-diagnosed Ph-like DSMKF, and relapsed/refractory Ph+ patients without prior
             dasatinib or other 2nd or 3rd generation TKI therapy, must have achieved CR or CRi
             within 1 cycle of induction with dasatinib/prednisone, or within 2 cycles of
             re-induction with blinatumomab; relapsed/refractory Ph+ or Ph-like DSMKF patients with
             prior dasatinib or other 2nd or 3rd generation TKI therapy must have achieved CR or
             CRi within 2 cycles of re-induction therapy with blinatumomab

               -  NOTE: day 1 of post-remission = day 85 of the preceding
      
Maximum Eligible Age:N/A
Minimum Eligible Age:65 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Overall survival (Cohort I)
Time Frame:From the day of registration on study until death from any cause, assessed at 3 years
Safety Issue:
Description:The final analysis will test whether the observed 3-year overall survival is improved over an historical rate of 10% with a one-sided binomial test at the 0.04 level. In the event of censoring, the 3-year overall survival rate will be estimated using the method of Kaplan-Meier and a one-sided 90% confidence interval will be constructed with the standard error calculated using the log-log transformation.

Secondary Outcome Measures

Measure:Complete response (complete remission + complete remission with incomplete count recovery) rate (Cohort I)
Time Frame:Up to 10 years
Safety Issue:
Description:Estimated with a 95% confidence interval.
Measure:Disease-free survival
Time Frame:From the date the patient first achieves complete remission or complete remission with incomplete count recovery until relapse from complete remission/complete remission with incomplete count recovery or death from any cause, assessed up to 10 years
Safety Issue:
Description:Distributions of disease-free survival will be estimated using the method of Kaplan-Meier.
Measure:Response rates (Cohort II)
Time Frame:Up to 10 years
Safety Issue:
Description:Estimated with a 95% confidence interval.
Measure:Overall survival (Cohort II)
Time Frame:Up to 10 years
Safety Issue:
Description:Estimated using the method of Kaplan-Meier.
Measure:Incidence of toxicity
Time Frame:Up to 10 years
Safety Issue:
Description:Graded according to graded according to NCI CTCAE version 4.0 (CTCAE version 5.0 will be used for SAE reporting only). Estimated with a 95% confidence interval.
Measure:Minimal residual disease negativity
Time Frame:Up to 10 years
Safety Issue:
Description:Will be examined separately in descriptive analyses within each cohort.
Measure:Time to achieve minimal residual disease negativity
Time Frame:Up to 10 years
Safety Issue:
Description:Will be examined separately in descriptive analyses within each cohort.

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:National Cancer Institute (NCI)

Last Updated